Cipla Q2 Results FY24-25 Highlights: Cons Revenue at ₹7,051 Cr Up 9%, PAT at ₹1,303 Cr Surged 17% YoY

    Listen to our Podcast: Grow your wealth and keep it secure.

    0:00 / 0:00

    Synopsis:

    Cipla Limited has reported consolidated Q2 results for FY24-25, showcasing a steady rise in financial performance. The company recorded a revenue of ₹7,051 Cr, an 8.6% YoY increase, and a PAT of ₹1,303 Cr, marking a 16.9% growth. This growth is attributed to strong sales across segments, particularly in India and North America.

    Key Highlights/Quick Insights

    • Total Revenue: ₹7,051 Cr (8.6% YoY growth)
    • EBITDA: ₹1,886 Cr, with an 11.6% YoY increase
    • PAT: ₹1,303 Cr, reflecting a 16.9% increase
    • EBITDA Margin: 26.7%, a 70 basis points rise
    • PAT Margin: 18.5%, an improvement of 130 basis points

    Cipla Ltd

    Trade

    14647.30 (0.50 %)

    Updated - 02 July 2026
    1468.20day high
    DAY HIGH
    1458.00day low
    DAY LOW
    37183
    VOLUME (BSE)

    Quarterly Performance – Cipla Q2 Results FY24-25

    Cipla’s quarterly performance has been buoyed by growth in domestic and North American markets, with substantial improvements in the chronic segment

    Other Income:Expenses:

    Metric

    Q2 FY25

    Q2 FY24

    YoY % Change

    Revenue from Operations

    ₹7,051 Cr

    ₹6,678 Cr

    8.60%

    EBITDA

    ₹1,886 Cr

    ₹1,689 Cr

    11.60%

    PAT

    ₹1,303 Cr

    ₹1,155 Cr

    16.90%

    EBITDA Margin

    26.70%

    26.00%

    +70 bps

    PAT Margin

    18.50%

    17.20%

    +130 bps

    Employee Benefits Expense

    ₹1,208 Cr

    ₹1,091 Cr

    9%

    Depreciation & Amortization

    ₹272 Cr

    ₹290 Cr

    -6%

    Segment Highlights

    One India:North America:Africa and Emerging Markets:

    Sector Expectations for Cipla 2Q Results FY24-25

    Cipla's results align with sector expectations, especially in chronic therapies like respiratory and cardiac, where growth continues despite industry challenges. The management's strategic focus on high-growth markets has been instrumental in surpassing sector benchmarks.

    Management Commentary

    Cipla’s management expressed satisfaction with the quarter’s performance, attributing growth to strategic launches and robust demand in core therapeutic areas. The leadership emphasized continued investment in R&D and expansion across high-growth segments.

    Check out Cipla's past performances in previous quarters and financial years. 

    Conclusion

    Cipla’s Q2 FY24-25 results underscore its growth trajectory in both domestic and international markets. With a strong pipeline, particularly in the North American generic segment, Cipla remains committed to sustainable growth. The company's strategic focus on key therapies and segments continues to drive value for stakeholders. 

    Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

    This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

    Share this article: 

    Published Date : 29 Oct 2024

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |